Prevalence of individual and most common combination of cardiometabolic outcomes by study inflammatory disorders
| CHD+T2DM | CHD+Stroke | CHD+VTE | CHD+PAD | VTE | T2DM | CHD | Stroke | PAD | Multiple | |
| RA | 66 (1) | 36 (1) | 48 (1) | 8 (0) | 269 (5) | 345 (6) | 484 (8) | 162 (3) | 52 (1) | 187(3) |
| Psoriasis | 71 (1) | 17(0) | 16 (0) | 6 (0) | 176 (3) | 367 (6) | 379 (6) | 103 (2) | 29 (1) | 127 (2) |
| AS | 18 (1) | 11 (1) | 8 (1) | 2 (0) | 45 (3) | 75 (5) | 100 (7) | 38 (3) | 8 (1) | 40 (3) |
| Vasculitis | 16 (1) | 11 (1) | 11 (1) | 1 (0) | 100 (7) | 83 (6) | 108 (7) | 48 (3) | 15 (1) | 54 (4) |
| SLE | 2 (0) | 9 (1) | 11 (2) | 4 (1) | 83 (13) | 27 (4) | 52 (8) | 39 (6) | 25 (4) | 33 (4) |
| UC | 26 (1) | 7 (0) | 21 (1) | 2 (0) | 148 (6) | 142 (5) | 172 (6) | 49 (2) | 15 (1) | 70 (3) |
| CD | 8 (1) | 7 (1) | 6 (0) | 0 (0) | 69 (5) | 53 (4) | 62 (4) | 23 (2) | 12 (1) | 25 (2) |
| Non-exposed | 3134 (1) | 1325 (0) | 1252 (0) | 197 (0) | 12 131 (3) | 19 949 (4) | 21 857(5) | 7425(2) | 1350 (0) | 6901 (1) |
The figures represent the number and percentage (brackets) of participants diagnosed with cardiometabolic events out of the total within each condition or non-exposed group.
AS, ankylosing spondylitis; CD, Crohn’s disease; CHD, coronary heart disease; Multiple, two or more outcome measures (participants from previous columns are also included in this column); PAD, peripheral artery disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T2DM, type 2 diabetes mellitus; UC, ulcerative colitis; VTE, venous thromboembolism.